A PYMNTS Company

France: Novartis, Roche fined millions in pay-for-delay scheme

By  |  March 5, 2014

French regulators fine Swiss pharmaceutical giants Novartis and Roche for their alleged anticompetitive pay-for-delay agreements that blocked the sale of a cheaper version of a Roche-made cancer drug, say reports.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Italy announced Wednesday that it has imposed a fine of $251 million on the companies after finding evidence the competing firms colluded to prevent the sale of Roche’s cheaper cancer drug Avastin, used to tread an eye disease, to allegedly place more market favor to Novartis’s Lucentis, which costs more.

    Reports say the companies partnered to market the more expensive drug.

    The two companies have denied the allegations and Roche has since vowed to appeal the fines, say reports. But the sanctions follow consumer advocacy group the European Consumer Organization’s calls for an EU-wide investigation into the practice of pharma giants colluding to block the sale of a cheaper drug to promote sales of a more expensive version of the same treatment, known as a pay-for-delay scheme.

    Full Content: Bloomberg

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.